Synthego, the leading genome engineering company, today announced the launch of genome engineering for induced pluripotent stem (iPS) cells. The new offering expands Synthego’s automated cell editing to achieve unprecedented editing efficiency of iPS cells at an industrial scale. The company simultaneously announced the National Institute on Aging (NIA) at the National Institutes of Health (NIH) has awarded Synthego a contract to create panels of mutations in a variety of genetic backgrounds to study Alzheimer's disease and related dementias (ADRD). Synthego also announced the addition of Dr. Bill Skarnes, a pioneer in stem cell research, to the company’s advisory board.
A fundamental challenge in research and therapeutic development is the lack of high quality, physiologically relevant biological models for translational medicine. iPS cells are reprogrammed human adult cells reverted to a stem cell state, and can provide one of the most reliable and accurate models for disease due to the ...
